Covid-19 roundup: Sanofi promis­es to bring re­com­bi­nant vac­cine ca­pac­i­ty to 1B+ while scal­ing up mR­NA man­u­fac­tur­ing

Sanofi be­lieves it’s lined up two of the best shots at a Covid-19 vac­cine by team­ing up with Glax­o­SmithK­line on the old­er re­com­bi­nant ap­proach and en­list­ing Trans­late Bio’s splashy mR­NA tech. And now the phar­ma gi­ant is bring­ing its man­u­fac­tur­ing ca­pac­i­ty up to match that.

Build­ing on a pre­vi­ous promise to sup­ply 100 to 600 mil­lion dos­es of a bac­ulovirus re­com­bi­nant vac­cine, Sanofi has set a goal to go be­yond 1 bil­lion dos­es with­in a year — echo­ing sim­i­lar am­bi­tions by its Big Phar­ma brethren J&J. On the mR­NA front, Sanofi said its part­ners can scale up to man­u­fac­ture 90 to 360 mil­lion dos­es by the first quar­ter of 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.